No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANRO Alto Neuroscience
- 14.480
- -0.020-0.14%
Trading Jul 16 09:42 ET
389.28MMarket Cap-9170P/E (TTM)
14.685High14.480Low14.76KVolume14.730Open14.500Pre Close215.73KTurnover0.16%Turnover RatioLossP/E (Static)26.88MShares24.00052wk High2.02P/B133.88MFloat Cap9.40052wk Low--Dividend TTM9.25MShs Float24.000Historical High--Div YieldTTM1.41%Amplitude9.400Historical Low14.616Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Alto Neuroscience Completes Enrollment In ALTO-100 Phase 2b Study, Topline Results Expected In October
Express News | Alto Neuroscience Inc - to Report Topline Data of Study in Oct 2024
Express News | Alto Neuroscience Announces Enrollment Completion in Phase 2B Study of Alto-100 in Major Depressive Disorder
Rodman & Renshaw Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $43
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Alto Neuroscience(ANRO.US)$ with a buy rating, and sets the target price at $43.According to TipRanks data, the analyst has a success rate
Alto Neuroscience Initiated at Buy by Rodman & Renshaw
Alto Neuroscience Initiated at Buy by Rodman & Renshaw
Express News | Rodman & Renshaw Initiates Coverage On Alto Neuroscience With Buy Rating, Announces Price Target of $43
Comments
$Alto Neuroscience(ANRO.US$
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
1
Investment firms see Alto Neuroscience's biomarker approach as a potential boost for clinical trials and patient outcomes. They predict a high stock risk/reward into 2H 2024/1H 2025 readouts, with a possible 100%-200% rise on positive data.
1
$Alto Neuroscience(ANRO.US$ let's get it
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
